Literature DB >> 9458096

Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients.

B P Kennedy1, C Soravia, J Moffat, L Xia, T Hiruki, S Collins, S Gallinger, B Bapat.   

Abstract

The synovial fluid or group II secretory phospholipase A2 (sPLA2) has been implicated in various inflammatory processes and has been shown to release arachidonic acid for prostaglandin biosynthesis. In human colorectal cancer, both arachidonic acid and eicosanoid levels are elevated. Recently, sPLA2 has been identified as a candidate gene that modifies the Apc gene in the Min mouse, a murine model for familial adenomatous polyposis (FAP). Loss of sPLA2 gene function results in susceptibility to the Min phenotype and the formation of multiple intestinal polyps, whereas mice expressing an active sPLA2 gene are resistant to polyp formation. Therefore, there are two potentially contrasting roles for sPLA2 in colon cancer; one is protection against polyp formation, and the other, the release of arachidonic acid for prostaglandin production and subsequent tumor promotion. To investigate these contrasting dual roles of sPLA2, we have examined the expression and sequence of the sPLA2 mRNA in normal mucosa and duodenal and colorectal polyps from FAP patients. In 11 of 14 patients, there was a significant increase in sPLA2 mRNA levels in the adenoma over the normal tissue. In some cases, there was over 100-fold increase in mRNA levels in the adenoma compared with normal tissue. Analysis of multiple adenomatous polyps from individual patients revealed that not all polyps contained elevated levels of sPLA2 mRNA. Immunoblot analysis also showed that sPLA2 protein expression was elevated in adenoma over normal tissue in five of six FAP patients analyzed. Furthermore, sequence analysis of sPLA2 mRNA present in these samples did not reveal mutations in the coding region. The implications of the up-regulation of sPLA2 in FAP is not clear, but unlike the Min mouse model, it does not seem to have a significant effect on polyp formation. In contrast, the high level of sPLA2 expression is more likely contributing to the elevated levels of arachidonic acid found in colorectal cancer and, in conjunction with the elevated expression of cyclooxygenase-2, could be another factor in tumor formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9458096

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  The Mediterranean diet: effects on proteins that mediate fatty acid metabolism in the colon.

Authors:  Zora Djuric
Journal:  Nutr Rev       Date:  2011-12       Impact factor: 7.110

2.  Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms.

Authors:  Mario Menschikowski; Albert Hagelgans; Eugene Gussakovsky; Heike Kostka; Elena L Paley; Gabriele Siegert
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

Review 3.  Roles of cPLA2alpha and arachidonic acid in cancer.

Authors:  Masako Nakanishi; Daniel W Rosenberg
Journal:  Biochim Biophys Acta       Date:  2006-09-15

4.  Expression of secreted phospholipase A2-Group IIA correlates with prognosis of gastric adenocarcinoma.

Authors:  Chengwei Zhang; Haipeng Yu; Haiyan Xu; Lanlan Yang
Journal:  Oncol Lett       Date:  2015-09-21       Impact factor: 2.967

5.  Inhibition of NFkappaB-mediated pro-inflammatory gene expression in rat mesangial cells by the enolized 1,3-dioxane-4, 6-dione-5-carboxamide, CGP-43182.

Authors:  K Scholz-Pedretti; W Eberhardt; G Rupprecht; K F Beck; S Spitzer; J Pfeilschifter; M Kaszkin
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  The expression and distribution of group IIA phospholipase A2 in human colorectal tumours.

Authors:  Tuulia Avoranta; Jari Sundström; Eija Korkeila; Kari Syrjänen; Seppo Pyrhönen; Jukka Laine
Journal:  Virchows Arch       Date:  2010-10-12       Impact factor: 4.064

7.  Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions.

Authors:  Ephraim P Lansky; Wenguo Jiang; Huanbiao Mo; Lou Bravo; Paul Froom; Weiping Yu; Neil M Harris; Ishak Neeman; Moray J Campbell
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

8.  Synthesis of oligo(ethylene glycol) substituted phosphatidylcholines: secretory PLA2-targeted precursors of NSAID prodrugs.

Authors:  Renato Rosseto; Joseph Hajdu
Journal:  Chem Phys Lipids       Date:  2010-01       Impact factor: 3.329

9.  Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.

Authors:  Christine Lagorce-Pagès; François Paraf; Dominique Wendum; Antoine Martin; Jean-François Fléjou
Journal:  Virchows Arch       Date:  2004-03-25       Impact factor: 4.064

10.  Nested case-control study on the risk factors of colorectal cancer.

Authors:  Kun Chen; Jian Cai; Xi-Yong Liu; Xi-Yuan Ma; Kai-Yan Yao; Shu Zheng
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.